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Background/aims: Controversial results have been found in literature for the association
between insulin resistance and sustained virologic response to standard chronic hepatitis C
treatment. This study aims to provide a systematic literature review with meta-analysis, in
order to evaluate if insulin resistance interfereswith sustained virologic response in patients
infected by the HCV genotype 1 versus HCV genotypes 2 and 3, undergoing treatment with
interferon and ribavirin or pegylated interferon and ribavarin.
Methods: Systematic search was performed on main electronic databases until May 2012.
Primary outcome was sustained virologic response, deﬁned as undetectable levels of HCV-
RNA six months after the end of treatment. Meta-analytic measure was estimated using
Dersimonian and Laird’s method, using Stata software.
Results: Thirteen studies involving 2238 infected patients were included. There was a sta-
tistically signiﬁcant association between insulin resistance and lower sustained virologic
response rate, and this difference occurred in HCV genotype G1 (OR: 2.23; 95% CI: 1.59–3.13)
and G2/G3 (OR: 4.45; 95% CI: 1.59–12.49). In addition, a difference was seen in the cut-offs
used for deﬁning insulin resistance byHomeostasisModelAssessment of Insulin Resistance.
To minimize this limitation, sub-analysis that excluded the studies that did not use 2 as a
cut-off value was performed and the results still demonstrated association between insulin
resistance and sustained virologic response, for both genotypic groups.
Conclusion: This meta-analysis provides evidence that elevated Homeostasis Model Assess-
ment of Insulin Resistance is associated with a lower sustained virologic response rate in
patients with hepatitis C treated with interferon and ribavirin or pegylated interferon and
ribavarin, regardless of their genotype.
© 2013 Elsevier Editora Ltda. All rights reserved.
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Introduction
Chronic infection by the hepatitis C (HCV) virus is considered
to be a major public health issue all over the world.1 Many
viral and host factors have been implicated in disease pro-
gression and/or response to antiviral treatment. Among those
factors insulin resistance (IR) is noteworthy. Different stud-
ies have demonstrated an association between HCV infection
and increase in IR prevalence.2–6 IR is the main pathophysio-
logical mechanism of the metabolic syndrome, depending on
the tissue sensitivity to insulin.2,5 In hepatitis C IR is related
to the presence of steatosis, faster ﬁbrosis progression and
increased risk of progression to cirrhosis and hepatocellular
carcinoma.4,6–8
Molecular studies have demonstrated the capacity of hep-
atitis C virus to promote IR by interfering with intracellular
insulin signaling, either by the virus itself or via an increase
in the tumor necrosis factor (TNF-) production. This cytokine
or viral core proteins can alter the residues of serine from the
insulin substrate 1 and 2 receptors, as well as the expression
of the cytokine suppressor substrate (SOCS). These changes
can block the transactivation of glucose transporters (GLUT-4)
in the cells, suppressing glucose uptake, leading to a hyper-
insulinism state.5,9–11 On the other hand, increasing SOCS-3
expression could reduce the response to treatment with inter-
feron and ribavirin (IFN+RBV).11,12 In fact, many studies
have demonstrated that the presence of IR, identiﬁed by the
HOMA-IR index (Homeostasis Model Assessment of Insulin
Resistance)13,14 is associated with lower rates of sustained
virologic response (SVR) to treatment with pegylated inter-
feron and ribavarin (PEG-IFN+RBV).15–19 Despite the evidence
shown in clinical and molecular studies, controversial results
have been found in clinical practice regarding the association
between IR and response to the standard antiviral treatment
for chronic hepatitis C.20–22
The recent introduction of protease inhibitors in the
treatment of genotype 1 carriers increases signiﬁcantly the
treatment response rate,whichdoesnot seemtobe inﬂuenced
by IR.23,24 Nonetheless these drugs are not recommended to
non-1 genotypes and, also, in many countries triple therapy
will not be available to all patients and PEG-IFN+RBV will
remain the standard treatment formany subjectswith chronic
hepatitis C.
The aim of the present study was to provide a systematic
literature reviewwithmeta-analysis, in order to evaluate if the
IR interferes with SVR in patients infected by the HCV geno-
type 1 (G1) versus HCV genotypes 2 and 3 (G2/G3), undergoing
treatment with IFN+RBV or PEG-IFN 2a or 2b+RBV.
Methods
Electronic search was performed on the MEDLINE database
(via PUBMED), Latin America and Caribbean Literature in
Health Sciences (LILACS), EMBASE, Cochrane Central Register
of Controlled Trials and The Cochrane Library until May 2012.
Electronic search was complemented by manual search from
bibliographic references and abstracts from selected papers.
The searchesweremade using thewords “genotype”, “hep-
atitis C” and “insulin resistance” via controlled vocabulary
MeSH for the PUBMED database and adapted to the other
databases, according to their speciﬁcities. Language or time
limits were not used.
The following pre-deﬁned inclusion criteria were: sys-
tematic reviews, clinical trials, prospective or retrospective
observational studies, which reported the correlation between
HOMA-IR andSVR, in subjects infected by theHCV (G1 orG2/3),
that were treatment naive, with 18 years old or above, from
any ethnic group. The exclusion criteria were: case reports;
studies not carried out in humans; coinfection with human
immunodeﬁciency virus (HIV), and those with subjects under-
going a therapy different from the ones deﬁned on this study
(PEG-IFN+RBV or IFN+RBV).
The main outcome was SVR, deﬁned by undetectable levels
of HCV-RNA six months after the end of the treatment.
Two reviewers performed the search on the database using
the strategies previously deﬁned and selected the trials to be
included in the review. Initially it was agreed that in case a
consensus was not achieved, a third reviewer would be con-
sulted regarding eligibility, and he would be responsible for
the ﬁnal decision.
The Stata software (11.2 version; Stata Corp., College
Station, TX, USA) was used for the statistical analysis. The
outcomeswere evaluated by dichotomous variables, for which
an odds ratio (OR) and a 95% conﬁdence interval (CI) were
calculated. A p-value≤0.05 was considered statistically sig-
niﬁcant. Initially the heterogeneity among the studies was
investigated with the Cochran’s Q test and I2 Higgins and
Thompson’s statistics, with equivalent signiﬁcances. Moder-
ate heterogeneity was identiﬁed for all the meta-analysis (I2
near 50% and less than 75%). Therefore, a random effects
model was considered and the meta-analytic measure (OR)
was estimated using Dersimonian and Laird’s method, based
on theassumption that there is heterogeneity among the stud-
ies.
Results
The systematic literature review performed in June 2012
resulted in 84 bibliographic references from PUBMED, 4 bib-
liographic references from LILACS and 247 bibliographic
references from EMBASE. After reading the titles and the
abstracts, 281 references that did not meet the eligibility crite-
ria or were duplicated, were excluded. Fifty-four papers were
selected for more detailed analysis of their contents. In addi-
tion, papers from reference lists of the 54 selected papers
and relevant paper reviews were added. At the end 13 studies
that met the inclusion criteria were considered in the meta-
analysis (Fig. 1).
Characteristics of the included studies
The characteristics of the included studies are described in
Table 1. All the studies included are complete articles pub-
lished in journals between 2005 and 2012. Most studies are
prospective, observational, with only one being retrospec-
tive. All included subjects were treated with PEG-IFN 2a or
2b+RBV, with duration depending on the viral genotype. For
IR deﬁnition, the HOMA-IR index>2 was considered, except
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Medine/Pubmed
all years
84 citations
Embase
all years
247 citations
The cochrane library
all years
0 citations
LILACS
all years
4 citations
Articles retrieves from
other sources
3 citations
302 non-duplicate
Citations
screened
Inclusion/Exclusion
criteria applied
54 articles retrieved
Inclusion/Exclusion
criteria applied
13 articles included
41 articles excluded
after full text screen
248 articles excluded
after title/Abstract screen
Fig. 1 – Fluxogram of studies selection.
in two studies that deﬁned it as HOMA-IR>2.5,19,25 one that
considered HOMA-IR>2.726 and another one that considered
HOMA-IR>3.21 HOMA-IR and SVR showed statistically sig-
niﬁcant association in eight studies and, according to the
genotypic classiﬁcation of HCV, seven studies demonstrated
positive association for the genotype 1 group and three stud-
ies for the genotypes 2 and 3. The other ﬁve studies did not
ﬁnd a signiﬁcant association between HOMA-IR and SVR.
Meta-analysis of the studies that evaluate the SVR rates
in subjects with HCV with and without IR deﬁned by a
cut-off value of HOMA-IR
Thirteen selected studies, involving 2238 subjects, were
included in the meta-analysis (Table 1). According to the
analysis including all selected studies, the SVR rates were
signiﬁcantly lower in subjects with IR, when compared to
thosewithout IR, regardless of the genotype, using the random
effects model by the Dersimonian and Laird’s method (OR:
2.43; 95% CI: 1.77–3.35) (Fig. 2). Results remained unchanged
even when studies that used for the deﬁnition of IR a HOMA-
IR>2.5 or >2.7 or 3 were excluded from the analysis (OR: 2.54;
95% CI: 1.67–3.87) (Fig. 3).
To evaluate SVR rates in subjects with or without IR consid-
ering speciﬁc genotypes, 12 studies were included involving
2156 subjects with HCV G1, among which ﬁve studies also
included subjects with other genotypes. Nevertheless, for the
analysis, only the speciﬁc results for HCV G1 were consid-
ered. For the analysis of genotypes 2 and 3, six studies were
included involving 552 subjects. Only results that reported
data for genotypes 2 and 3 were added to the analysis.
The analysis demonstrated a negative and statistically
signiﬁcant association between the HOMA-IR index and
SVR rates regardless of HCV genotypes: G1 (OR: 2.23; 95%
CI: 1.59–3.13) and G2/G3 (OR: 4.45; 95% CI: 1.59–12.49)
(Figs. 4 and 5). For each genotypic group (HCV G1 and HCV
G2/G3), the impact of IR on SVR rates was maintained, even
after the exclusion of the studies with HOMA-IR index cut-off
different from 2. (Data not shown – refer to supplementary
data.)
Discussion
This meta-analysis aimed to evaluate the impact of the IR
on the response to antiviral treatment with IFN-RBV or PEG-
IFN+RBV in subjects infected by HCV, taking into account
the genotypic group G1 versus G2/G3. Thirteen studies were
included involving 2238 infected subjects. The results demon-
strated a statistically signiﬁcant association between IR and
lower SVR rates, regardless of the genotypic group evaluated,
but was more evident on G2/G3: OR: 2.23; 95% CI: 1.59–3.13 and
OR: 4.45; 95%CI: 1.59–12.49, respectively forHCVG1 andG2/G3.
Among the selected studies for the meta-analysis, a differ-
ence in the cut-offs used for IR deﬁnition using the HOMA-IR
index was noted. To minimize this limitation, sub-analysis
that excluded the studies that did not use 2 as a cut-off value
braz j infect d i s . 2013;17(5):555–563 559
NOTE: Weights are from random effects analysis
Overall  (I-squared = 49.6%, p = 0.022)
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10.64 (3.06, 36.95)
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OR (95% CI)
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8.77 (1.87, 41.18)
1.69 (1.11, 2.58)
1.58 (0.58, 4.29)
5.03 (1.50, 16.82)
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13.86
7.31
5.43
Weight
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8.56
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13.67
6.50
5.03
%
6.21
1.0243 41.2
Heterogeneity Q = 23.79 (d.f. = 12) p = 0.022; I² = 49.6%; t² = 0.15; Test of OR = 1: p = 0.000
Fig. 2 – Odds-ratio for the association between IR and SVR. Global analysis, according to the cut-off deﬁnition of the
HOMA-IR index used in each study.
NOTE: Weights are from random effects analysis
Overall  (I-squared = 60.7%, p = 0.009)
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ID
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100.00
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Weight
1.0243 41.2
Heterogeneity Q = 20.33 (d.f. = 8) p = 0.009; I² = 60.7%; t² = 0.23; Test of OR = 1: p = 0.000
Fig. 3 – Odd-ratio for the association between IR and SVR. Analysis including only studies with HOMA-IR index cut-off > 2.
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 41.6%, p = 0.064)
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Heterogeneity Q = 18.82 (d.f. = 11) p = 0.064; I² = 41.6%; t² = 0.13; Test of OR = 1: p = 0.000 
Fig. 4 – Odds-ratio for the association between IR and SVR in subjects with HCV G1. Analysis according to the deﬁnition of
HOMA-IR index cut-off used in each study.
wasperformedand the results associationbetween IR andSVR
remained unchanged for both genotypic groups (Figs. 6 and 7).
The mechanism by which IR reduce the response to
antiviral treatment inpatientswithHCVhasnot yet been com-
pletely elucidated. Nonetheless, it is known that IR presents
different nuances according to the genotype. Therefore, while
steatosis in genotype 1 hepatitis C is clearly associated with
IR, in the genotype 3 carriers it seems to be caused basically
NOTE: Weights are from random effects analysis
Overall  (I-squared = 64.1%, p = 0.016)
Fattovich 2010
Eslam 2012
Miyaaki 2009
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ID
Dai 2009
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1.30 (0.69, 2.46)
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Heterogeneity Q = 13.91(d.f. = 5) p = 0.016; I² = 64.1%; t2 = 0.88; Test of OR = 1: p = 0.005 
Fig. 5 – Odds-ratio for the association between IR and SVR in subjects with HCV G2/G3. Analysis according to the deﬁnition
of HOMA-IR index cut-off used in each study.
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 58.8%, p = 0.017)
Fattovich 2010
Romero-Gomez 2005
Mizuta 2010
ID
Grasso 2009
Chu 2008
Eslam 2012
Miyaaki 2009
Conjeevaram 2007
Study
2.54 (1.57, 4.11)
1.11 (0.62, 2.01)
3.13 (1.42, 6.88)
5.98 (1.76, 20.32)
OR (95% CI)
1.58 (0.58, 4.29)
10.64 (3.06, 36.95)
3.82 (1.09, 13.36)
2.65 (0.72, 9.80)
1.69 (1.11, 2.58)
100.00
17.51
14.49
9.36
Weight
11.72
9.15
9.08
8.60
20.10
%
1.0271 36.9
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Fig. 6 – Odds-ratio for the association between IR and SVR in subjects with HCV G1. Study analysis of HOMA-IR index
cut-off > 2.
by viral cytopathic effect.27,28 In this way, it is important to
evaluate if IR interferes with the antiviral treatment response
in patients with different genotypes. The studies available in
the literature suggest an important role of IR in the patho-
genesis of hepatitis C in response to the antiviral therapy
related to the virus genotypes, specially among subjects with
G1 HCV infection.15,18,29 In the study by Romero-Gomez and
collaborators,15 it was demonstrated that IR strongly inﬂu-
enced SVR rates in patients infected by HCV G1, which varied
from 60% in patients without IR to only 20% in patients with
HOMA-IR>4. In this way, HOMA-IR index could be introduced
as a predictive marker of SVR in patients infected by HCV G1.
NOTE: Weights are from random effects analysis
Overall  (I-squared = 72.0%, p = 0.013)
ID
Poustch 2008
Study
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Miyaaki 2009
Eslam 2012
5.32 (1.12, 25.27)
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100.00
Weight
27.76
%
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14.27
22.07
1.00503 199
Heterogeneity Q = 10.73 (d.f. = 3) p = 0.013; I² = 72%; t² = 1.65; Test of OR = 1: p = 0.036 
Fig. 7 – Odds-ratio for the association between IR and SVR in subjects with HCV G2/G3. Analysis including only studies with
HOMA-IR index cut-off > 2.
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The multicentric study Virahep-C also evaluated how much
IR interferes with SVR.29 This study was designed to evalu-
ate the rates and predictors of SVR among Afro-American and
Caucasian subjects infected by the HCV G1 under treatment
with a combination of PEG-IFN+RBV. The HOMA-IR index
value correlated signiﬁcantlywith SVR rates (highest SVR rates
were associated with lowest HOMA-IR index value). In addi-
tion, the HOMA-IR value decreased during therapy between
responders and non-responders, but this reduction was only
statistically signiﬁcant among those who achieved SVR. Chu
and collaborators18 reported that IR played a decisive role on
SVR in the treatment with PEG-IFN+RBV in Chinese subjects
infected with HCV G1. Other studies support the data previ-
ously reported for G1.19,21,30–33
Currently, interest in the study of genotypes 2 and 3
has increased and two meta-analyses were conducted to
demonstrate the relevance of IR in these cases. However, no
comparisons versus genotype 1 were performed.34,35 In 2011,
Eslam and collaborators published a meta-analysis aiming
to evaluate the impact of IR on SVR in hepatitis C, but all
genotypes were studied in this analysis (1, 2, 3 and 4), with
no distinction among them.34 The study concluded that the
increase in the HOMA-IR index was associated with lower
therapeutic response in subjects infected by HCV.
A study published in 2008 by Poustchi and collaborators16
demonstrated that IR was an independent predictor of lower
SVR in subjects infected by genotypes 2 or 3 (OR for no-
response with HOMA-IR>2=6.5; 95% CI: 1.3–31.9; p=0.02).
Another study in 62 subjectswithdifferentHCVgenotypes (G1,
G2 andG3) has demonstrated that SVRwas reduced inpatients
with HOMA-IR>3, but this difference was not sustained when
analyzed for each genotype individually, due to the limited
number of subjects in each subgroup.21 However, Eslam30 with
the purpose to investigate the effect of IR on SVR in 263 sub-
jects with chronic hepatitis C, demonstrated that SVR rate
was signiﬁcantly reduced among patients with HOMA-IR≥2
for each genotype analyzed (G1, G3, and G4). This difference
was maintained even when different cut-off values of HOMA-
IR were used to deﬁne IR (>3 and >4). As such, the presence of
IR,measured by theHOMA-IR index, presents prognostic value
for standard therapy (PEG-IFN+RBV) also in patients with G2
or G3. This therapy tends to remain the standard treatment
for these genotypes over the next years in Brazil.
Despite these results, the SVR variation according to
HOMA-IR values remains a controversial issue, as some
studies do not conﬁrm that IR can play an important role
in SVR.20,25,26,31 Fattovich et al.20 reported an association
between HOMA-IR and rapid virologic response (RVR), but it
was not predictive of SVR, in the entire cohort and also in
HCV genotypes subgroups. In the same way, two other studies
evaluating the response to therapy in subjects infected by G1
only reported association with RVR and IR, but did not ﬁnd any
signiﬁcant association with SVR.26,31 Dai and Thompson sug-
gested in their studies that viral eradication was associated
with IR in patients infected by G1, but such association was
not seen in patients infected by G2 or G3.19,22
This meta-analysis included the studies previously men-
tioned, initially assessing presence or absence of IR, regardless
of the cut-off value used in HOMA-IR and, subsequently,
including only thosewith cut-off value ≥2. On both itwas clear
that the presence of IR was associated with reduced SVR rates
in patients infected by HCV G1 and G2/G3, and that HOMA-IR
index canbeusedas apredictive factor for SVR inpatientswith
G1, as well as on those with G2/G3. This an important point
once there is no consensus regarding the HOMA-IR value lim-
its that deﬁnes IR because values of 2; 2.5; 2.7 and 3 have been
used. Besides, further studies to assess SVR in patientswithG2
and G3 should be conducted to strengthen pre-existing data
on its association with IR.
The discrepancy among the results in the selected studies
must take into consideration that the interaction between IR
and SVR also depends on other factors that need to be consid-
ered in the data interpretation. Besides the cut-off value used
in the deﬁnition of IR, basal characteristics of the study cohort
and the technical adequacy in collecting and measuring the
serum insulin sample are of paramount importance. In this
last case, different assays can present signiﬁcant differences
in determining serum insulin levels.36 On the other hand, both
fasting glucose levels and serum insulin levels are potentially
modiﬁable factors on a short period of time, through lifestyle
changes (diet and exercise) as well as a result of medication.
Thus, patients with chronic hepatitis C that are candi-
dates to antiviral therapy with PEG-IFN+RBV must be checked
for IR before being started on treatment since HOMA-IR
index presents a prognostic value for SVR in these patients,
regardless of their genotypes. Although controversial, the
modulation of insulin signaling and improvement in IR and
serum glucose control should be attempted aiming at a better
therapeutic response.37
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